NF1 MEK Inhibitors: What to Expect Before and During Treatment

What MEK inhibitor treatment can offer

For some people with neurofibromatosis type 1 (NF1), MEK inhibitors offer a way to treat plexiform neurofibromas that cause symptoms and cannot be fully removed with surgery. These noncancerous tumors grow along nerves and may lead to pain, changes in appearance or difficulty with everyday activities. Because they can be intertwined with nearby tissue, complete surgical removal is not always possible or safe.

Mirdametinib (Gomekli) and selumetinib (Koselugo) are oral medicines used for adults and children with symptomatic plexiform neurofibromas that can’t be completely removed. They reduce activity in a cell signal that helps tumor cells grow. Treatment aims to shrink tumors or slow their growth, while supporting a person’s comfort and ability to function.

Starting a medicine that may be taken for months or years is a substantial decision. Neurologist Pierre Giglio, MD, says treatment should be reassessed over time: the care team can monitor the tumor’s response, address side effects and consider whether the benefits continue to outweigh the risks. Starting treatment doesn’t mean having to continue regardless of how it affects you.

Preparing for treatment and ongoing checks

Before the first dose, expect baseline eye, heart and blood tests. The MEK pathway is active in healthy cells as well as tumor cells, so treatment can affect parts of the body beyond the tumor. Nicholas A. Blondin, MD, says these initial results help clinicians identify changes during treatment and decide whether a dose adjustment or stopping the medicine should be considered.

An eye exam checks for possible effects on the retina, the light-sensitive tissue at the back of the eye. An echocardiogram uses ultrasound to assess how well the heart pumps. Blood tests can include liver and kidney function, electrolytes and creatine phosphokinase (CPK), an enzyme that may rise when muscles are affected.

Monitoring continues after treatment starts. Checkups and blood tests may happen about monthly at first, then every few months. Heart and eye assessments may be scheduled about every three months during the first year. MRI scans, often every three to six months, help track the tumor. Because some side effects can emerge later, checks continue for as long as treatment does.

Schedules, food and practical details

Both medicines are taken by mouth twice daily, with doses based on height and weight. They can be taken with or without food. Their schedules differ: mirdametinib is taken for three weeks, followed by one week without doses, in repeating four-week cycles. Since a 28-day cycle doesn’t match a calendar month, marking the break and restart dates may help. Selumetinib is taken twice a day every day, without a scheduled break.

Linking doses to familiar morning and evening routines, such as brushing your teeth, and using a chart to record them can support consistency. Follow the medicine-specific instructions from your care team and pharmacist. Capsules should be swallowed whole, not opened, chewed or crushed. If swallowing is difficult, ask about other forms: mirdametinib is also available as tablets that dissolve in water, and selumetinib as granules that can be sprinkled on yogurt or fruit puree.

If you vomit after taking a dose, the source guidance is to wait until the next scheduled dose rather than take another. Instructions for a missed dose depend on the medicine: for mirdametinib, skip it; for selumetinib, take it when remembered unless the next dose is due within six hours. Confirm what to do with your own care team or pharmacist, particularly if your situation differs from these instructions.

Selumetinib capsules should remain in their original bottle to protect them from moisture, rather than being moved into a pill organizer. The capsules contain vitamin E, which may increase bleeding risk for people taking a blood thinner. Tell the prescriber and pharmacist about blood thinners and other medicines you use.

Side effects and when to contact the care team

Common side effects include rash, sometimes with acne-like bumps; diarrhea; nausea or vomiting; fatigue; muscle, joint or bone pain; and stomach problems. Stomach symptoms, fatigue and muscle soreness may start in the first few weeks, while a rash may take longer to appear. Some side effects can be serious enough to require a dose change or stopping treatment.

Early contact can help the care team respond before a manageable problem worsens. Skin care, treatment for a rash, or medicines for nausea and diarrhea may help; in some cases, rash treatment can begin before the first dose. A treatment break, dose adjustment or another medicine may also be considered. More side effects do not mean the drug is working better, and patients do not need to endure symptoms silently. MEK inhibitors can increase sun sensitivity, so sunscreen and protective clothing are practical precautions.

Contact the care team promptly about new or worsening vision changes, such as blurred vision, flashes or changes in the field of vision. Shortness of breath, new leg swelling, unusual fatigue with difficulty breathing or a racing heart also warrants prompt attention. So do severe or ongoing diarrhea or vomiting that prevents you from keeping fluids down, a significant skin reaction, or unusual muscle pain or weakness. A neurofibroma that grows suddenly, persistent or quickly worsening pain, or new neurological symptoms should also be reported for assessment.

Arranging access

These medicines are generally obtained through specialty pharmacy services rather than a neighborhood drugstore. Mirdametinib is distributed through a specialty pharmacy network. Selumetinib may be shipped by a specialty oncology pharmacy that handles insurance approval, or filled through a hospital system’s pharmacy. The manufacturers offer help with insurance and copays; some people without adequate coverage may qualify for free or lower-cost medication. Ask the care team how to start the process, since arranging access can take coordination.